Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

Table 1

Evaluable patients*	Melanoma	RCC	TCC	NSCLC	EA	SCCHN
n(%)	(n=7)	(n=5)	(n=2)	(n=2)	(n=2)	(n=1)
ORR (CR+PR)	4 (57)	2 (40)	1 (50)	1 (50)	1 (50)	1 (100)
CR	2 (29)	0	0	0	0	0
PR	2 (29)	2 (40)	1 (50)	1 (50)	1 (50)	1 (100)
SD	2 (29)	2 (40)	0	1 (50)	0	0
DCR (CR+PR+SD)	6 (86)	4 (80)	1 (50)	2 (100)	1 (50)	1 (100)
PD	1 (14)	0	1 (50)	0	0	0
Not assessable	0	1 (20)	0	0	1 (50)	0

*Patients with ≥ 1 post-baseline response assessment or discontinued from study or died before response could be assessed.